The phase 2 SORMAIN study evaluated 83 patients with FLT3-ITD-positive AML after HSCT and demonstrated that the hazard ratio (HR) for relapse or death was 0.39 in the sorafenib versus placebo group [39]. The gene discussed is FLT3; the disease is acute myeloid leukemia.